Company Presentation - Cytori Therapeutics, Inc. CYTORI THERAPEUTICS, INC. :: Marc Hedrick, President (NASDAQ: CYTX) Cytori is developing cell therapies for the treatment of cardiovascular disease, burns an... By: AllianceRegenMed … Continue reading →

A KEY TO REGENERATIVE MEDICINE: Discovery of a new adult stem cell with special properties Learn about the exciting discovery that could revolutionize regenerative medicine by providing a source to produce organs derived from a patient's own stem c... By: YourekaScience … Continue reading →

By SCOTT ROTHSCHILD, The Lawrence Journal-World In a mix of science and anti-abortion politics, Gov. Sam Brownback on Monday signed into law a bill that establishes the nation's first adult stem cell research and treatment center at the Kansas University Medical Center. "I am honored to sign this bill of hope and promise and current treatments," Brownback said. Brownback described adult stem cell and umbilical cord blood research as an "exploding" area of new discoveries to treat people with a wide range of diseases. "KU will be the leader, Kansas will be the leader, which is fabulous in this burgeoning field," he said. But the bill carried political overtones. It was sponsored by vehement abortion opponents and pushed by the Family Research Council, a conservative Christian lobbying group. In addition, KU never asked for the legislation establishing what will be known as the Midwest Stem Cell Center, and the Legislature has yet to produce the estimated $1.1 million needed for the center's startup. The center is prohibited from using embryonic stem cells or cells taken from aborted fetal tissue. Abortion opponents oppose human embryonic stem cell research because it involves the destruction of the embryo. Dr. Buddhadeb Dawn, director of … Continue reading →

WASHINGTON, April 22, 2013 /PRNewswire-USNewswire/ -- Family Research Council (FRC) congratulated Kansas Governor Sam Brownback and the state of Kansas for the passage and signing of Kansas SB 199. The law establishes a new adult stem cell research and treatment center at the University of Kansas Medical Center in Kansas City's medical school. (Logo: http://photos.prnewswire.com/prnh/20080930/FRCLOGO) FRC 's Senior Fellow Dr. David Prentice has testified in Kansas for years about the benefits of ethical adult stem cell treatments, based on their published scientific record. He promoted the idea of an adult stem cell center in talks with legislators, educators, doctors, and patients. He also helped write the legislation, and served as a scientific witness in legislative testimony. Of the bill signing Dr. Prentice said: "With the signing of SB 199, Governor Sam Brownback has taken the first step toward making Kansas an international hub for scientific advancement and life-saving treatment. Through the creation of the Midwest Stem Cell Therapy Center, Gov. Brownback has demonstrated a commitment to both scientific advancement and a culture of life. "This bill would not have passed without the effort of Senator Mary Pilcher-Cook, who authored and sponsored the bill and has worked tirelessly for years to … Continue reading →

TOPEKA, Kan. (AP) Gov. Sam Brownback signed legislation Monday aimed at making Kansas the national leader in treatments using adult stem cells and umbilical cord blood by requiring the state's medical school to establish a new research center. The new Midwest Stem Cell Therapy Center to be set up at the University of Kansas Medical Center in Kansas City is the brainchild of anti-abortion legislators and has the strong backing of other abortion opponents. The new law, taking effect in July, will prohibit the center from using its funds or facilities for research with embryonic stem cells or cells from fetal tissue. But Brownback also was flanked by medical patients as he signed the bill creating the new research center. Among them was Mary Lou Rusco, a 64-year-old retired telecommunications worker from Wichita who was diagnosed with leukemia in 2007 and has seen her cancer remain in remission since receiving cells from two babies' umbilical cord blood in 2009. "I really appreciate the fact that Kansas is doing this so that other people can have access to this," she said. Stem cells are thought to have the ability to change in different types of cells, and researchers see promise in … Continue reading →

LA JOLLA, Calif., April 23, 2013 /PRNewswire/ -- Today, over 23.5 million people suffer from over eighty different types of known autoimmune diseases.Unfortunately, treatment for those suffering from non-curable autoimmune diseases has been limited to: To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/stemgenex-on-exciting-new-adult-stem-cell-based-therapies-for-auto-immune-diseases-204279071.html With the recent emergence of regenerative medicine, doctors and medical groups around the world are developing new techniques to help treat suffering patients. New scientific and medical findings in regenerative medicine are leading to natural alternative treatments and advancements that are life altering. The body's immune system is a complex network of special cells and organs that defends the body from germs and other foreign invaders. In order for the immune system to function properly, it needs the ability to tell the difference between what's you and what's foreign. When the immune system cannot, it attacks normal cells by mistake. The result of these misguided attacks is what is known as autoimmune disease. Some common autoimmune diseases are: What's exciting today is that new techniques through clinical studies are underway and they are helping unlock the code to our regenerative anatomy. For instance, studies using stem cells and gene therapy have shown great … Continue reading →

RANCHO MIRAGE, Calif.--(BUSINESS WIRE)-- Leaders in the field of stem cell research and clinical utilization will convene in Rancho Mirage for Select Biosciences Clinical Translation of Stem Cells Summit, announced David M. Morrow, MD, founder and director of The Morrow Institute, local host for the conference. The event will be held from 9 a.m. 5 p.m. on April 22-23 at the Rancho Las Palmas Resort followed by 6 p.m. practicums at The Morrow Institute. Focusing on the safe and effective use of regenerative techniques, the summit will be chaired by Lee Buckler, Managing Director, Cell Therapy Group, and will feature presentations by international, national and local experts. Presenters include Kotaro Yoshimura, MD, Department of Plastic Surgery, University of Tokyo; Mark Berman, MD, President, American Academy of Cosmetic Surgery, California Stem Cell Treatment Center; Ingrid Caras, PhD, Senior Science Officer, California Institute for Regenerative Medicine; Prudence Talbot, MD, Director, UC Riverside Stem Cell Center; David Morrow, MD and Allan Wu, MD, co-founders of The Morrow Institutes Non-Controversial Stem Cell Research Lab; and others. Dr. Wu will be the keynote speaker the first day of the conference. Richard Kite, mayor of Rancho Mirage, will present a proclamation to the event organizers; American … Continue reading →

New IBN Peptides May Help Researchers Combat Alzheimer's, Diabetes and Cancer Singapore, Apr 22, 2013 - (ACN Newswire) - Amyloids, or fibrous aggregates of abnormally folded proteins, are a common feature in degenerative diseases such as Alzheimer's, diabetes and cancer. Amyloids occur naturally in the body, but despite decades of research, their mechanism of formation remains unknown, hampering drug development efforts. Now, a new class of ultrasmall peptides developed by the Institute of Bioengineering and Nanotechnology (IBN) offers scientists a platform for understanding this phenomenon, providing them with the insights required to design more effective treatments for these diseases. IBN Executive Director Professor Jackie Y. Ying said, "Our researchers have been focusing on creating biomimetic materials for nanomedicine and cell and tissue engineering applications. The novel ultrasmall peptides developed by IBN are not only highly effective as synthetic cell culture substrates, but also as a model for studying the mystery of amyloid formation. Such fundamental understanding could contribute towards advancing medical treatment of amyloid-related disorders." First discovered in 2011 by IBN Team Leader and Principal Research Scientist Dr Charlotte Hauser, the peptides were formed from only 3-7 amino acids, making them the smallest ever reported class of self-assembling aliphatic compounds. … Continue reading →

A small Cambridge biotech has inked three deals this year with major drug firms Amgen, Pfizer and now AstraZeneca which could net $1 billion for the maker of nanoparticles that promise to deliver drugs more efficiently to where they are needed in the body. This is a clear indication that nanomedicine has reached an inflection point, said Scott Minick, CEO of BIND Therapeutics. The pharmaceutical industry is realizing its a very important technology. Founded in 2007, BINDs revolutionary drug delivery system grew out of a collaboration between MIT Professor Robert Langer and Professor Omid Farokhzad of Harvard Medical School. Yesterday, BIND Therapeutics and AstraZeneca announced a deal to develop and commercialize a cancer nanomedicine. The companies will work together to complete new studies of a specific Accurin, BINDs name for customized nanomedicine particles that selectively accumulate in diseased tissues and cells, leading to higher drug concentrations at the site of a tumor and reduced exposure to healthy tissues. AstraZeneca will then have the exclusive right to lead development and commercialization, and BIND will lead manufacturing during the development phase. AstraZeneca believes that targeted therapies which specifically address the underlying mechanisms of disease are the future of personalized cancer treatment, Susan … Continue reading →

BOSTON - A small Cambridge biotech has inked three deals this year with major drug firms -- Amgen, Pfizer and now AstraZeneca -- which could net $1 billion for the maker of nanoparticles that promise to deliver drugs more efficiently to where they are needed in the body. "This is a clear indication that nanomedicine has reached an inflection point," said Scott Minick, CEO of BIND Therapeutics. "The pharmaceutical industry is realizing it's a very important technology." Founded in 2007, BIND's revolutionary drug delivery system grew out of a collaboration between MIT Professor Robert Langer and Professor Omid Farokhzad of Harvard Medical School. Yesterday, BIND Therapeutics and AstraZeneca announced a deal to develop and commercialize a cancer nanomedicine. The companies will work together to complete new studies of a specific Accurin, BIND's name for customized nanomedicine particles that selectively accumulate in diseased tissues and cells, leading to higher drug concentrations at the site of a tumor and reduced exposure to healthy tissues. AstraZeneca will then have the exclusive right to lead development and commercialization, and BIND will lead manufacturing during the development phase. "AstraZeneca believes that targeted therapies which specifically address the underlying mechanisms of disease are the future of … Continue reading →